Pharmalink AB, a Swedish specialty pharma company, has entered into a contract with Patheon for the manufacture of Nefecon, Pharmalink’s lead product. Nefecon is being developed as the first on-label medication aimed at addressing the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease. Nefecon was granted an orphan drug designation by the FDA. Financial terms were not disclosed. Johan Hägg...